Abbott Laboratories: FY2023 Form 10-K Summary
Business context and reporting period
Abbott Laboratories is a diversified global health-care company operating through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The filing covers the fiscal year ended December 31, 2023. Although the request references 2023 Q4, this Form 10-K does not present standalone fourth-quarter financial statements; the summary below uses full-year results.
Abbott generated approximately 61% of sales outside the United States and employed approximately 114,000 people at year-end. Its products include branded generic pharmaceuticals, diagnostic systems and tests, pediatric and adult nutrition products, cardiovascular and neuromodulation devices, and diabetes-care products.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $40.109 billion | $43.653 billion | Down 8.1% |
| Operating earnings | $6.478 billion | $8.362 billion | Down 22.5% |
| Operating margin | 16.2% | 19.2% | Down 3.0 percentage points |
| Net earnings | $5.723 billion | $6.933 billion | Down 17.5% |
| Diluted EPS | $3.26 | $3.91 | Down 16.6% |
| Net cash from operations | $7.261 billion | $9.581 billion | Down 24.2% |
| Capital expenditures | $2.202 billion | $1.777 billion | Up 23.9% |
Gross margin declined to 50.3% from 51.5%, primarily because of lower COVID-19 testing sales, unfavorable foreign exchange, and higher manufacturing input costs. Research and development expense was $2.741 billion, compared with $2.888 billion in 2022, while selling, general and administrative expense was $10.949 billion, compared with $11.248 billion.
Cash and cash equivalents were $6.896 billion at December 31, 2023, compared with $9.882 billion at year-end 2022. Cash, cash equivalents, and short-term investments totaled approximately $7.3 billion. Working capital was $8.8 billion, compared with $9.7 billion in 2022.
Total debt was approximately $14.7 billion, down from $16.8 billion at year-end 2022, including $1.080 billion classified as current. Approximately $1.1 billion of principal was scheduled to mature in 2024. Abbott reported AA- and Aa3 long-term debt ratings from S&P Global Ratings and Moody’s, respectively, and had access to up to $5 billion under unsecured credit facilities. The company expects to fund 2024 pension contributions of approximately $350 million.
Abbott paid $3.556 billion in dividends during 2023 and declared dividends of $2.08 per share, compared with $1.92 per share in 2022. It repurchased approximately 9.8 million shares for $1.025 billion, with approximately $1.41 billion remaining under its repurchase authorization at year-end.
Segment results and material changes
| Segment | 2023 sales | 2023 operating earnings | Key change |
|---|---|---|---|
| Established Pharmaceuticals | $5.066 billion | $1.206 billion | Sales up 10.9% excluding foreign exchange; operating earnings up 15.0% |
| Nutritional Products | $8.154 billion | $1.333 billion | Sales up 11.6% excluding foreign exchange; operating earnings up 88.9% |
| Diagnostic Products | $9.988 billion | $2.433 billion | Sales down 38.2% excluding foreign exchange; operating earnings down 63.4% |
| Medical Devices | $16.887 billion | $5.306 billion | Sales up 15.1% excluding foreign exchange; operating earnings up 19.6% |
- COVID-19 testing-related sales fell to approximately $1.6 billion from $8.4 billion in 2022 and $7.7 billion in 2021. Abbott expects demand to remain unpredictable in 2024.
- Excluding COVID-19 testing sales, total sales increased 9.2%; excluding both COVID-19 testing and foreign exchange, sales increased 11.7%.
- Medical Devices growth was led by Diabetes Care, Electrophysiology, Structural Heart, Heart Failure, Neuromodulation, and Vascular. FreeStyle Libre sales reached $5.3 billion, up 25.5% excluding foreign exchange.
- Nutritional Products benefited from recovery in U.S. pediatric nutrition following the 2022 infant-formula recall and production stoppage. Abbott regained the leading U.S. infant-formula market position by volume in the fourth quarter of 2023.
- Established Pharmaceuticals grew across emerging markets, including India, Vietnam, and Brazil.
- Abbott completed the $851 million acquisition of Cardiovascular Systems, Inc. and acquired Bigfoot Biomedical; neither acquisition materially affected consolidated 2023 revenue or earnings.
- Abbott recorded approximately $175 million of 2023 restructuring, impairment, and inventory-related charges, including $144 million of employee-related restructuring charges and $31 million of fixed-asset and inventory charges.
Outlook, commentary, risks, and contingencies
Management’s 2024 priorities are to expand Alinity and rapid diagnostics, grow newly launched medical-device products, expand nutrition products globally, and continue building the emerging-market pharmaceutical portfolio. Abbott targeted research and development spending at approximately 7% of 2024 sales. The filing does not provide a clear consolidated 2024 sales or earnings guidance figure.
- Infant formula matters: Abbott continues to face lawsuits involving specialty preterm infant formula; 993 federal and state lawsuits were pending as of January 31, 2024. The Department of Justice, SEC, and Federal Trade Commission also had investigations or information requests related to infant formula manufacturing, disclosures, or WIC bidding.
- Tax exposure: Abbott received a $417 million IRS notice of deficiency related primarily to income allocation between U.S. entities and foreign affiliates for 2019 and has challenged it in Tax Court. Unrecognized tax benefits totaled approximately $3.3 billion at year-end, of which approximately $1.22 billion would affect the effective tax rate if recognized.
- Legal and environmental matters: Estimated possible losses for legal proceedings and environmental exposures were $30 million to $45 million, with approximately $40 million accrued. Management stated that these matters are not expected to have a material adverse effect, although outcomes remain uncertain.
- Product and regulatory risk: Abbott faces extensive FDA and international regulation, potential recalls, product-liability claims, intellectual-property disputes, reimbursement and pricing pressure, and changing medical-device and diagnostic requirements.
- Operational risk: Key risks include supply-chain disruption, manufacturing problems, cybersecurity incidents, foreign-exchange volatility, inflation, geopolitical instability, and dependence on successful product development and regulatory approvals.
- COVID-19 products: Abbott is pursuing customary regulatory approvals for certain tests previously sold under Emergency Use Authorizations. The U.S. public health emergency ended May 11, 2023, while demand for COVID-19 testing has substantially declined.
- Controls and audit: Management and Ernst & Young concluded that internal control over financial reporting was effective as of December 31, 2023. The financial statement audit opinion was unqualified; income taxes and unrecognized tax benefits were identified as the critical audit matter.
Most important facts for investors to verify
- Whether Medical Devices growth, particularly FreeStyle Libre, can offset continued normalization of COVID-19 testing revenue.
- The sustainability of the U.S. pediatric nutrition recovery and the potential financial impact of infant-formula litigation, investigations, and regulatory requirements.
- Progress toward reducing debt while funding acquisitions, capital expenditures, dividends, repurchases, and approximately $350 million of expected 2024 pension contributions.
- The outcome and potential cash-tax impact of the $417 million IRS notice of deficiency and other unresolved tax positions.
- Whether gross-margin improvement initiatives can offset foreign-exchange, inflation, manufacturing, and product-mix pressures.
- Future regulatory approvals, product launches, patent disputes, cybersecurity events, and changes in reimbursement or health-care pricing policy.